DAB1 rs116417497: cancer link and gene expression
Upload your raw genetic data once, we'll show you which variants you carry and what the research says.
Key takeaways
- This variant is linked to higher risk of high-grade astrocytoma with an effect size of 2.37 and p=9e-6 in about 9 000 people.
- It increases DAB1 expression in breast tissue by about 0.56 log₂ units (p=7.9e-5).
- The association is based on a genome-wide association study.
Key takeaways
- This variant is linked to higher risk of high-grade astrocytoma with an effect size of 2.37 and p=9e-6 in about 9 000 people.
- It increases DAB1 expression in breast tissue by about 0.56 log₂ units (p=7.9e-5).
- The association is based on a genome-wide association study.
What the research says This variant is associated with high-grade astrocytoma and increases DAB1 expression in breast tissue. The GWAS shows an effect size of 2.37 (p=9e-6) for the cancer risk and a GTEx signal of +0.56 log₂ units (p=7.9e-5). 36810956
Reported associations Astrocytoma high-grade: the variant is linked to higher risk with an effect size of 2.37 and p=9e-6 in about 9 000 people 36810956. Breast tissue: DAB1 expression is increased by about 0.56 log₂ units (p=7.9e-5) GTEx Portal.
Evidence quality The GWAS used about 9 000 individuals and the variant shows a strong association (p=9e-6) for high-grade astrocytoma. The GTEx signal is also significant (p=7.9e-5). No conflicting studies are provided.
Tissue-specific expression effects
- DAB1: increased expression in breast tissue GTEx Portal. No lifestyle considerations on file for this variant.
Frequently asked questions
What does rs116417497 mean?
It is a genetic change in the DAB1 gene that has been linked to higher risk of high-grade astrocytoma and increased expression of the gene in breast tissue.
Is this variant dangerous?
The evidence shows an association with cancer but it does not cause disease on its own. Risk depends on many factors.
Does it affect how I feel?
No, the study only looks at biological effects; there are no reported symptoms or health impacts for carriers.